[The clinical efficacy and safety of intravenous levofloxacin in the treatment of 4888 patients with bacterial infections: a multi-center trial].
OBJECTIVE
To evaluate the clinical efficiency and safety of intravenous levofloxacin in the treatment of bacterial infections at a dose of 500 mg once a day.


METHODS
Randomized, prospective, multicenter, open-label study.


RESULTS
The total effective rate of levofloxacin was 90.8% (4103/4521). The effective rates of levofloxacin in the treatment of bacterial infections of respiratory tract, urinary tract, digestive tract and gynecologic infections and infections complicated with hematological disease were 90.2% (2884/3198), 92.3% (810/878), 91.9% (203/221), 94.5% (120/127), 88.7% (86/97), respectively. The bacterial eradication rate was 80.3% (677/843). The most common adverse drug reactions were gastrointestinal disorders (3.9%, 193/4888) and local irritation (1.7%, 84/4888), which were mild and disappeared after stopping administration.


CONCLUSIONS
Intravenous levofloxacin with a dose of 500 mg once a day is effective and safe in treating bacterial infections with low adverse reactions.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use*; D011446:Prospective Studies; D055815:Young Adult
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin